The levels of CD68, a macrophage marker, correlated with an adverse prognosis in glioblastoma, kidney renal clear cell carcinoma, hepatocellular carcinoma, lung squamous cell carcinoma, and thyroid carcinoma and a favorable prognosis in colorectal cancer, OS, and kidney chromophobe (44–49). This evidence concerns the gene CD68 and hepatocellular carcinoma.